Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 22;43(2):16.
doi: 10.1007/s12640-025-00742-6.

Oxytetracycline and its Non-Antibiotic Derivative DOT Protect Midbrain Dopamine Neurons from Iron-Driven Oxidative Damage

Thaís Antonia Alves Fernandes  1   2   3 , Aurore Tourville  1 , Ismaila Ciss  1   4 , Rafaela Ribeiro Silva  1 , Bianca Andretto de Mattos  1   2   3 , Maurício Dos Santos Pereira  1   5 , Maxime Oblaza  1   4 , Jean-Michel Brunel  6 , Laurent Ferrié  4 , Rita Raisman-Vozari  1 , Bruno Figadère  4 , Elaine Del-Bel  7 , Patrick Pierre Michel  8
Affiliations

Oxytetracycline and its Non-Antibiotic Derivative DOT Protect Midbrain Dopamine Neurons from Iron-Driven Oxidative Damage

Thaís Antonia Alves Fernandes et al. Neurotox Res. .

Abstract

This study aimed to investigate the neuroprotective potential of the tetracycline (TC) antibiotic oxytetracycline (OT) and its non-antibiotic derivative 4-dedimethylamino 12a-deoxy-oxytetracycline (DOT), in experimental conditions that mimic the gradual loss of dopamine (DA) neurons in Parkinson's disease (PD). Specifically, we established a model system of mouse midbrain cultures where DA neurons progressively die when exposed to an iron-containing medium. We found that OT (EC50 = 0.25µM) and DOT (EC50 = 0.34µM) efficiently protected DA neurons from degeneration, with these effects observable until advanced stages of neurodegeneration. The reference antibiotic TC doxycycline (DOX) also exhibited protective effects in this context. Importantly, DA neurons rescued by OT, DOT, and DOX retained their capacity to accumulate and release DA, indicating full functional integrity. Additionally, molecules with iron-chelating properties (apotransferrin, desferoxamine), as well as inhibitors of lipid peroxidation and ferroptosis (Trolox, Liproxstatin-1), could replicate the rescue of DA neurons provided by OT, DOT, and DOX. Live-cell imaging studies showed that test TCs and other neuroprotective molecules prevented the emission of intracellular reactive oxygen species and the associated disruption of the mitochondrial membrane potential. However, neither OT, DOT, nor DOX could protect DA neurons from selective mitochondrial poisoning by 1-methyl-4-phenylpyridinium. This suggests that test TCs may be protective against iron-mediated damage through a mechanism not directly involving mitochondria. Overall, we demonstrate that OT and DOT possess promising properties that could be useful for combating PD neurodegeneration. However, the absence of antimicrobial activity makes DOT a better candidate drug compared to its parent compound OT.

Keywords: Dopamine; Iron; Neurodegeneration; Non-antibiotic tetracyclines; Oxidative stress; Parkinson’s disease.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing Interests: P.P.M., R.R-V., E.D.B., L.F., and B.F. have filed patent applications for the treatment of Parkinson’s disease and related disorders using non-antibiotic tetracycline derivatives.

References

    1. Abou-Sleiman PM, Muqit MM, Wood NW (2006) Expanding insights of mitochondrial dysfunction in Parkinson’s disease. Nat Rev Neurosci 7(3):207–219. https://doi.org/10.1038/nrn1868 - DOI - PubMed
    1. Ammendolia DA, Bement WM, Brumell JH (2021) Plasma membrane integrity: implications for health and disease. BMC Biol 19(1):71. https://doi.org/10.1186/s12915-021-00972-y - DOI - PubMed - PMC
    1. Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Gross CE (2001) Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-lesioned macaque model of Parkinson’s disease. J Neurosci 21(17):6853–6861. https://doi.org/10.1523/JNEUROSCI.21-17-06853.2001 - DOI - PubMed - PMC
    1. Bloem BR, Okun MS, Klein C (2021) Parkinson’s disease. Lancet 397:2284–2303. https:// - DOI - PubMed
    1. Bose A, Beal MF (2016) Mitochondrial dysfunction in Parkinson’s disease. J Neurochem 139(Suppl 1):216–231. https://doi.org/10.1111/jnc.13731 - DOI - PubMed

LinkOut - more resources